inflex
exist
serolog
techniqu
detect
rabi
surveil
constrain
benefit
gain
mani
current
control
strategi
analys
serum
sampl
tanzanian
dog
detect
rabi
antibodi
pseudotyp
assay
use
lentivir
vector
bear
envelop
glycoprotein
compar
wide
use
gold
standard
fluoresc
antibodi
viru
neutralis
assay
specif
sensit
strong
correl
antibodi
titr
r
observ
pseudotyp
assay
increas
assay
surveil
specif
africa
incorpor
envelop
glycoprotein
local
virus
lago
bat
viru
duvenhag
viru
mokola
viru
also
clone
lacz
gene
provid
report
element
neutralis
assay
use
pseudotyp
bear
glycoprotein
reveal
provid
greater
sensit
compar
similar
live
viru
assay
therefor
allow
accur
determin
distribut
highli
pathogen
infect
threat
pose
human
health
importantli
pseudotyp
highli
stabl
freezethaw
cycl
storag
room
temperatur
result
suggest
propos
pseudotyp
assay
suitabl
option
undertak
lyssaviru
serosurveil
area
affect
infect
rabi
spread
alarm
rate
region
develop
world
collabor
effort
among
human
anim
healthcar
profession
requir
monitor
situat
allow
time
proport
therapeut
respons
limit
unnecessari
use
valuabl
vaccin
combin
rabi
awar
campaign
improv
vaccin
coverag
diseas
surveil
alreadi
result
success
elimin
canin
rabi
north
america
howev
vaccin
need
efficaci
enough
elicit
respons
confer
protect
diagnost
techniqu
need
ensur
adequ
level
virusneutralis
antibodi
vnab
achiev
respons
vaccin
problem
current
test
easili
use
endem
area
within
develop
countri
need
set
contain
laboratori
sinc
highli
pathogen
zoonot
virus
requir
perform
assay
assay
prohibit
expens
eg
elisabas
assay
sensit
specif
fluoresc
antibodi
viru
neutralis
favn
assay
wide
use
within
offic
intern
de
oie
rabi
refer
laboratori
therefor
addit
need
implement
develop
improv
antirabi
biolog
improv
techniqu
assess
seroconvers
requir
canin
rabi
success
owner
invit
bring
dog
two
session
first
sampl
collect
baselin
measur
rabi
vaccin
administ
welfar
assess
conduct
twentyon
day
later
revisit
bs
villag
day
postvaccin
dog
sampl
collect
c
sampl
process
use
protocol
level
haemolysi
serum
collect
variabl
affect
result
fulli
elimin
develop
countri
north
america
within
lyssaviru
genu
classic
rabi
virus
genotyp
pathogen
caus
morbid
mortal
mammalian
popul
clearli
infect
lyssavirus
genotyp
result
clinic
manifest
indistinguish
rabi
genotyp
distribut
geograph
predominantli
within
african
european
australian
bat
popul
recent
addit
variant
diverg
genotyp
isol
suggest
genotyp
may
yet
exist
isol
repres
genotyp
identifi
insectivor
fruit
vampir
bat
mokola
viru
mokv
genotyp
along
lago
bat
viru
lbv
genotyp
duvenhag
viru
duvv
genotyp
compris
african
lyssavirus
interestingli
clinic
isol
repres
genotyp
identifi
date
hand
case
report
given
us
limit
understand
epidemiolog
zoonot
threat
genotyp
pose
respect
host
recent
surveil
program
greater
access
serosurveil
techniqu
result
discoveri
high
seropreval
lbv
east
west
african
megachiroptera
common
presenc
lbv
south
african
bat
collect
routin
surveil
report
other
emphasis
potenti
increas
incid
level
rabi
relat
lyssaviru
infect
concern
africa
mainli
lack
awar
infect
popul
howev
also
poor
access
vaccin
postexposur
treatment
expos
virus
difficulti
undertak
sero
surveil
measur
mani
countri
within
africa
import
factor
reduc
rabi
preval
implement
vaccin
campaign
highlight
recent
southern
eastern
african
rabi
group
meet
poor
infrastructur
becom
major
barrier
attempt
control
rabi
africa
view
share
oie
world
health
organ
list
develop
novel
diagnost
urgent
requir
serolog
techniqu
employ
studi
natur
occur
vaccineinduc
humor
respons
rabi
viru
infect
includ
favn
assay
rapid
fluoresc
focu
inhibit
test
rffit
enzym
link
immunosorb
assay
elisa
variat
assay
describ
previous
routin
use
favn
assay
rffit
current
assay
choic
oiewho
refer
laboratori
must
perform
high
contain
facil
live
viru
handl
part
assay
modifi
rffit
combin
green
fluoresc
protein
gfp
live
recombin
viru
remov
need
expens
conjug
work
recombin
viru
still
requir
use
high
contain
facil
recent
addit
mention
set
neutralis
assay
elisabas
method
use
plate
coat
whole
inactiv
viru
need
live
viru
elimin
sinc
nonneutralis
neutralis
antibodi
detect
level
circul
protect
vnab
alon
determin
also
issu
low
sensit
use
elisa
recent
describ
use
surrog
virus
known
lentivir
pseudotyp
replac
live
inactiv
whole
viru
accur
determin
antirabi
vnab
respons
vaccin
recipi
sampl
test
taken
vaccin
human
dog
cat
unit
kingdom
uk
report
result
largest
viru
neutralis
studi
publish
date
use
surrog
lentivir
pseudotyp
rather
live
nativ
recombin
rabi
viru
field
serum
sampl
tanzanian
dog
increas
util
pseudotyp
neutralis
assay
laboratori
undertak
vaccin
trial
serosurveil
resourcelimit
rabi
endem
countri
explor
use
lacz
report
gene
incorpor
glycoprotein
three
lyssaviru
primari
refer
dog
never
receiv
rabi
vaccin
prior
studi
booster
refer
dog
previous
receiv
rabi
vaccin
record
mean
vaccin
histori
avail
taken
one
sampl
miss
arriv
uk
b
one
sampl
vial
empti
arriv
uk
genotyp
addit
genotyp
allow
improv
serosurveil
lyssavirus
classic
rabi
report
describ
highli
sensit
yet
flexibl
platform
adapt
allow
evalu
vaccin
antivir
drug
highli
pathogen
virus
without
need
high
level
contain
facil
expens
reagent
equip
dog
enrol
studi
select
domest
anim
live
four
villag
ngarawani
rungabur
nyamburi
bisarara
within
km
serengeti
nation
park
perimet
serengeti
district
northwestern
tanzania
fig
case
dog
owner
consent
sought
enrol
dog
studi
project
part
annual
vaccin
campaign
undertaken
viral
transmiss
dynam
project
work
prevent
spread
diseas
anim
popul
serengeti
region
detail
medic
histori
dog
enrol
studi
includ
prior
vaccin
taken
first
visit
sixtysix
half
percent
n
dog
vaccin
rabi
prior
studi
refer
primari
n
receiv
least
one
rabi
vaccin
previous
booster
vaccin
histori
avail
taken
n
record
tabl
nobivac
rabi
viru
vaccin
donat
intervet
scheringplough
anim
health
administ
dog
singl
dose
inocul
given
subcutan
compris
inactiv
vaccin
contain
iu
rabi
viru
pasteur
strain
first
visit
blood
sampl
taken
dog
rabi
viru
vaccin
administ
second
visit
day
postvaccin
optimum
time
detect
immun
respons
stimul
vaccin
overal
studi
protocol
shown
fig
blood
drawn
cephal
jugular
vein
store
ice
process
end
day
centrifug
rpm
min
serum
prepar
inactiv
c
min
frozen
transport
total
sampl
taken
enrol
dog
blind
sent
univers
colleg
london
ucl
veterinari
laboratori
agenc
vla
test
oie
standard
refer
dog
serum
dilut
intern
unitsml
iuml
pb
use
posit
control
rabbit
antisera
rais
lbv
isol
n
duvv
isol
n
use
neutralis
assay
african
lyssaviru
pseudotyp
antisera
mokv
avail
antilbv
serum
known
crossneutralis
mokv
one
serum
rais
uninfect
tissu
cultur
supernat
anoth
australian
bat
lyssaviru
use
panel
lbv
duvv
sera
human
embryon
kidney
cell
use
product
lentivir
pseudotyp
lyssaviru
surrog
neutralis
assay
undertaken
babi
hamster
kidney
cell
clone
bhk
human
glioma
cell
line
express
use
target
cell
pseudotyp
live
viru
experi
undertaken
use
restrict
version
favn
ident
exist
favn
assay
serum
sampl
dilut
final
titr
roughli
equival
iuml
standard
plasmid
transfect
protocol
lentivir
pseudotyp
lyssaviru
surrog
product
describ
elsewher
addit
glycoprotein
g
gene
sequenc
lbv
access
number
mokv
access
number
duvv
access
number
amplifi
pcr
use
specif
primer
detail
supplementari
tabl
pseudotyp
contain
envelop
gene
gener
use
psviiienv
g
gene
sequenc
analysi
undertaken
use
clustalw
treeview
infect
neutralis
assay
use
lyssaviru
pseudotyp
perform
previous
describ
follow
three
modif
plate
centrifug
rpm
viru
ad
follow
addit
bhk
cell
ensur
oie
standard
refer
dog
serum
record
ic
dilut
approxim
tcid
pseudotyp
use
serum
dilut
final
titr
pseudotyp
report
gene
enabl
pseudotyp
particl
detect
use
appropri
substrat
construct
pcslzw
contain
lacz
gene
pmfgnlslacz
kind
gift
dr
yasuhiro
takeuchi
clone
pcsgw
primer
detail
supplementari
tabl
report
protein
cell
detect
strong
correl
favn
pseudotyp
neutralis
antibodi
titr
use
tanzanian
dog
sera
neutralis
titr
achiev
pseudotyp
assay
increas
concordantli
detect
favn
assay
distribut
accord
vnab
titr
determin
b
pseudotyp
c
favn
assay
sera
collect
first
visit
primari
dog
receiv
previou
rabi
vaccinationblack
column
booster
dog
receiv
rabi
vaccin
previouslygrey
column
dog
vaccin
record
white
column
shown
similar
analys
sampl
collect
second
visit
shown
e
pseudotyp
favn
assay
respect
dot
line
mark
level
vnab
achiev
oie
posit
control
serum
percent
sampl
inadequ
adequ
vnab
respons
given
left
right
dot
line
respect
vaccin
histori
avail
dog
first
visit
primari
n
booster
n
record
n
second
visit
primari
n
booster
n
record
n
f
result
pseudotyp
neutralis
favn
assay
reveal
high
degre
concord
sn
sensit
sp
specif
strong
correl
r
titr
sn
sp
rel
iuml
threshold
rp
valu
calcul
use
pearson
productmo
correl
arrow
indic
vnab
titr
serum
sampl
contain
level
antibodi
use
xgal
sigma
chlorophenol
redbetadgalactopyranosid
cprg
sigma
onitrophenylbdgalactopyranosid
onpg
sigma
detect
use
xgal
substrat
accomplish
fix
infect
cell
monolay
stain
cell
substrat
buffer
mm
deoxychol
acid
mm
potassium
ferrocyn
mm
potassium
ferricyn
mm
magnesium
chlorid
vv
contain
mgml
xgal
cprg
onpg
substrat
nuclei
lyse
l
reaction
buffer
mm
na
hpo
mm
nah
po
mm
mgcl
mm
ad
contain
cprg
onpg
final
concentr
mgml
respect
reaction
tabl
distribut
sera
accord
favn
neutralis
antibodi
titr
percentag
given
proport
categori
total
number
column
sampl
posit
favn
assay
neg
pseudotyp
assay
inhibit
h
c
ad
stop
solut
sodium
carbon
gfp
luciferas
report
gene
employ
detect
gfpposit
cell
visualis
use
fluoresc
microscop
facscalibur
bd
bioscienc
luciferas
express
detect
use
brightglo
reagent
glomax
micropl
luminomet
promega
dog
enrol
studi
mean
age
year
femal
tabl
total
sampl
taken
visit
tabl
howev
transport
one
sampl
disappear
one
leak
serum
remain
remain
sampl
volum
small
test
favn
assay
three
sampl
could
initi
test
pseudotyp
assay
contamin
toxic
remain
sampl
test
assay
type
serum
process
time
kept
constant
possibl
vari
degre
haemolysi
volum
sera
produc
vari
collect
fig
haemolysi
affect
result
obtain
either
favn
pseudotyp
assay
sera
fail
achiev
antibodi
titr
pseudotyp
assay
lowest
record
result
dilut
use
given
arbitrari
titr
analysi
oie
posit
control
serum
routin
neutralis
pseudotyp
particl
dilut
studi
oie
mean
dilut
standard
deviat
live
dilut
normal
equival
iuml
favn
assay
studi
oie
mean
dilut
standard
deviat
lowest
titr
serum
sampl
given
favn
assay
studi
iuml
dog
vnab
level
attain
ic
dilut
greater
equal
pseudotyp
assay
titr
iuml
favn
assay
consid
posit
also
refer
adequ
studi
result
favn
pseudotyp
assay
compar
observ
concurr
increas
vnab
titr
report
pseudotyp
assay
favn
titr
increas
fig
discord
sampl
classifi
neg
pseudotyp
assay
posit
favn
assay
tabl
result
averag
titr
sampl
classifi
borderlin
posit
favn
assay
iuml
borderlin
neg
result
pseudotyp
assay
discord
sampl
reduc
sensit
pseudotyp
neutralis
assay
specif
assay
n
major
discrep
cluster
around
iuml
titr
achiev
use
oie
posit
control
serum
current
use
classifi
vnab
respons
inadequ
level
achiev
oie
posit
control
serum
adequ
level
greater
equal
achiev
oie
posit
control
serum
twelv
discord
result
lowest
dilut
classifi
posit
favn
assay
iuml
one
fell
within
iuml
categori
three
iuml
categori
one
score
iuml
favn
assay
tabl
discrep
result
achiev
use
favn
pseudotyp
assay
sampl
second
visit
prior
vaccin
first
visit
result
use
pseudotyp
assay
classifi
dog
never
vaccin
tabl
titr
record
discord
sera
use
favn
pseudotyp
assay
vaccin
histori
avail
dog
record
b
serum
sampl
taken
dog
rabi
vaccin
histori
prior
studi
primari
radial
tree
panel
show
degre
glycoprotein
ident
viral
titr
lyssaviru
pseudotyp
envelop
g
gene
lbv
mokv
duvv
clone
titr
compar
achiev
pseudotyp
bear
g
ident
fulllength
g
amino
acid
sequenc
use
construct
tree
viral
titr
assess
use
gfp
carri
pseudotyp
given
ifuml
branch
length
scale
correspond
number
amino
acid
substitut
per
site
primari
inadequ
level
vnab
fig
compar
determin
favn
assay
fig
roughli
equal
split
inadequ
vs
adequ
level
vnab
vs
dog
receiv
one
rabi
vaccin
previous
booster
test
use
pseudotyp
assay
fig
discrep
result
describ
caus
balanc
shift
favour
adequ
vnab
level
vs
sera
analys
favn
assay
fig
sera
second
visit
assay
detect
three
dog
fail
achiev
level
vnab
greater
oie
control
serum
despit
receiv
vaccin
fig
e
none
three
dog
given
rabi
vaccin
prior
studi
level
circul
vnab
inadequ
visit
analysi
result
show
titr
record
serum
favn
pseudotyp
assay
correl
strongli
r
p
pearson
productmo
correl
fig
clone
g
gene
sequenc
lbv
mokv
duvv
express
plasmid
test
abil
incorpor
lentivir
pseudotyp
particl
use
gfp
marker
infect
bhk
cell
observ
compar
titr
lbv
mokv
pseudotyp
achiev
use
ifuml
respect
fig
titr
record
pseudotyp
express
duvv
g
higher
ifuml
test
specif
african
lyssaviru
pseudotyp
neutralis
assay
run
sera
rais
lbv
serum
no
duvv
serum
no
isol
neutralis
titr
pseudotyp
correl
strongli
titr
observ
use
favn
assay
tabl
antilbv
sera
crossneutralis
mokv
favn
pseudotyp
assay
howev
favn
assay
fail
detect
antiduvv
vnab
serum
low
level
serum
ic
compar
pseudotyp
assay
record
ic
titr
sera
respect
tabl
neg
control
australian
bat
lyssaviru
ablv
sera
achiev
ic
genotyp
either
assay
crossneutralis
duvv
lbv
sera
observ
tabl
broaden
lyssaviru
pseudotyp
platform
clone
lacz
gene
report
use
panel
serum
sampl
select
contain
low
medium
high
vnab
titr
ran
parallel
assay
determin
use
lacz
report
gene
instead
luciferas
alter
high
correl
r
p
pearson
productmo
correl
fig
sensit
specif
respect
titr
achiev
use
favn
assay
flexibl
use
differ
readout
key
requir
assay
use
africa
must
also
robust
abl
withstand
fluctuat
temperatur
therefor
test
stabil
pseudotyp
stock
store
differ
condit
freezethaw
cycl
pseudotyp
reveal
averag
decreas
viral
titr
per
cycl
pseudotyp
bear
vsv
envelop
protein
lost
respect
fig
compar
pseudotyp
stock
store
c
aliquot
store
room
temperatur
averag
c
halflif
week
increas
week
aliquot
c
pseudotyp
store
c
rel
stabl
month
fig
stabil
similar
observ
rv
duvv
pseudotyp
bear
vsv
envelop
glycoprotein
greater
halflif
pseudotyp
bear
hiv
envelop
glycoprotein
store
c
room
temperatur
data
shown
inclus
lacz
report
gene
increas
applic
pseudotyp
system
resourcelimit
laboratori
allow
determin
vnab
titr
without
need
expens
regent
equip
cell
infect
laczbas
pseudotyp
subsequ
stain
one
three
substrat
punctat
blue
stain
infect
cell
nuclei
achiev
presenc
xgal
fig
far
left
panel
also
adapt
assay
allow
colorimetr
substrat
cprg
onpg
use
fig
second
left
middl
panel
chang
result
vnab
titr
record
use
micropl
reader
read
nm
cprg
nm
onpg
simpli
eye
incorpor
lacz
addit
option
much
use
gfp
luciferas
report
gene
allow
highthroughput
approach
far
greater
expens
fig
second
right
far
right
panel
respect
mass
cull
stray
dog
previous
shown
ineffect
control
spread
rabi
practic
adopt
number
countri
contrari
dog
vaccin
program
enorm
success
control
canin
rabi
improv
diagnost
enabl
rapid
serosurveil
countri
undertak
program
therefor
import
assay
report
offer
practic
effect
robust
solut
rapid
lyssaviru
serosurveil
use
lentivir
pseudotyp
accur
measur
concentr
vnab
coupl
use
lacz
report
gene
pseudotyp
particl
product
remov
need
high
contain
laboratori
expens
equip
reagent
allow
assay
undertaken
laboratori
previous
unabl
use
exist
favn
furthermor
assay
restrict
lyssaviru
serosurveil
highli
pathogen
virus
pseudotyp
could
incorpor
platform
knowledg
largest
studi
publish
date
use
pseudotyp
diagnost
format
serosurveil
sampl
receiv
titr
three
could
determin
use
pseudotyp
assay
one
low
level
contamin
two
caus
cellular
cytotox
assay
issu
overcom
use
higher
concentr
antibiot
increas
number
bhk
cell
use
per
assay
comparison
sampl
could
titrat
favn
assay
insuffici
serum
volum
serum
volum
vari
sampl
suffici
volum
sampl
run
duplic
pseudotyp
neutralis
assay
highlight
anoth
major
advantag
use
pseudotyp
surrog
virus
neutralis
assay
small
serum
vol
fig
repertoir
report
gene
carri
within
pseudotyp
expand
rang
report
gene
enabl
neutralis
assay
perform
much
greater
number
laboratori
previous
possibl
laczbas
pseudotyp
detect
xgal
cprg
onpg
substrat
turn
blue
red
yellow
presenc
enzym
respect
gfp
appear
green
cytoplasm
stain
oxid
luciferas
substrat
result
light
emiss
detect
luminomet
vnab
virusneutralis
antibodi
concentr
arrow
indic
zero
luciferas
activ
ume
less
live
viru
assay
requir
assay
addit
import
benefit
pseudotyp
flexibl
choos
report
gene
depend
oper
requir
studi
luciferasebas
pseudotyp
use
allow
highthroughput
screen
sampl
permit
mani
plate
analys
short
period
howev
luciferas
reagent
plate
reader
expens
contrast
reagent
lacz
report
system
time
less
expens
luciferas
time
less
expens
fluorescein
isothiocyan
conjug
use
favn
assay
addit
neutralis
assay
use
pseudotyp
safer
requir
facil
overal
cost
use
mani
fold
lower
compar
perform
favn
assay
therebi
allow
expans
rabi
serosurveil
resourcelimit
laboratori
addit
sinc
pseudotyp
carri
lacz
report
detect
use
xgal
cprg
onpg
flexibl
assay
increas
colorimetr
substrat
possibl
record
vnab
titr
simpli
look
assay
plate
record
colour
chang
neutralis
assay
use
pseudotyp
lacz
report
also
use
semihighthroughput
screen
use
elispot
xgal
stain
micropl
reader
cprg
onpg
stain
howev
flexibl
offer
packag
lacz
gfp
luciferas
pseudotyp
particl
alon
make
assay
attract
option
use
laboratori
undertak
lyssaviru
serosurveil
stabil
pseudotyp
report
also
make
assay
suitabl
use
countri
infrastructur
coldchain
may
unreli
stock
pseudotyp
particl
thaw
refrozen
store
temperatur
c
would
still
viabl
use
subsequ
neutralis
assay
major
advantag
live
viru
viru
titr
decreas
rapidli
freezethaw
storag
c
howev
possibl
stock
pseudotyp
maintain
c
store
aliquot
reduc
number
time
vial
thaw
futur
consider
freez
dri
pseudotyp
particl
avoid
coldchain
storag
increas
eas
transport
number
inadequ
versu
adequ
vaccin
respond
detect
type
assay
compar
either
visit
collect
serum
howev
discord
result
observ
pseudotyp
favn
assay
partial
explain
fact
close
iuml
threshold
assay
variabl
favn
assay
mean
sampl
score
iuml
variabl
rang
iuml
test
repeat
twelv
sampl
iuml
titr
favn
assay
might
classifi
neg
retest
would
result
new
sensit
score
convers
also
possibl
score
iuml
obtain
favn
assay
correspond
titr
achiev
use
pseudotyp
assay
could
chang
retest
worth
note
dog
classifi
inadequ
vnab
respons
use
pseudotyp
assay
disagr
favn
result
sampl
vaccin
trial
addit
sampl
dog
histori
previou
rabi
vaccin
vaccin
year
studi
began
therefor
level
vnab
could
decreas
time
one
vaccin
histori
collect
trial
discord
result
coupl
neutralis
data
show
duvv
pseudotyp
detect
vnab
antiduvv
serum
detect
favn
assay
suggest
pseudotyp
assay
may
specif
sensit
detect
seroconvers
favn
assay
iuml
cutoff
use
howev
confirm
observ
studi
requir
use
analog
viral
isol
serum
larger
sampl
size
introduct
lbv
mokv
duvv
g
bind
antigen
pseudotyp
platform
coupl
exist
pseudotyp
mean
serum
screen
detect
vnab
six
differ
lyssaviru
genotyp
particular
import
larg
proport
assay
perform
sera
bat
small
volum
serum
avail
time
emerg
infecti
diseas
outbreak
becom
frequent
potenti
spread
faster
intern
travel
technolog
advanc
infecti
diseas
research
make
assay
rapid
facilit
autom
howev
countri
outbreak
like
occur
often
unabl
utilis
new
techniqu
address
limit
develop
assay
use
infecti
diseas
serosurveil
monitor
vaccin
respons
within
lowcontain
laboratori
neutralis
assay
base
pseudotyp
sourc
target
antigen
use
platform
use
start
new
outbreak
rabi
also
envelop
rna
virus
sar
coronavirus
influenza
ebola
virus
incorpor
lyssavir
envelop
protein
g
pseudotyp
platform
creat
assay
allow
rapid
screen
vaccin
evalu
perform
within
week
start
epidem
